MINNEAPOLIS--(BUSINESS WIRE)--April 18, 2006--MGI PHARMA, INC. (Nasdaq:MOGN - News), an oncology- and acute care-focused biopharmaceutical company, today announced publication of data from a randomized, controlled phase 3 trial (study 0007) of Dacogen(TM) (decitabine) for Injection in the journal Cancer. Dacogen is an investigational drug currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of patients with myelodysplastic syndromes (MDS). The Prescription User Fee Act (PDUFA) goal date for Dacogen is May 15, 2006.
